Holen Sie sich die Stockscreener-App
4.17
3.99%
0.16
Handel nachbörslich:
4.17
Schlusskurs vom Vortag:
$4.01
Offen:
$3.97
24-Stunden-Volumen:
365.28K
Relative Volume:
2.24
Marktkapitalisierung:
$170.66M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$109.16M
KGV:
1.6141
EPS:
2.5835
Netto-Cashflow:
$-9.11M
1W Leistung:
+10.61%
1M Leistung:
+4.51%
6M Leistung:
+41.36%
1J Leistung:
+97.63%
1-Tages-Spanne:
$3.96
$4.20
1-Wochen-Bereich:
$3.765
$4.20
52-Wochen-Spanne:
$1.975
$5.01
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.17 | 158.79M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
468.42 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.03 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.40 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.20 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.51 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
ORMP SEC FilingsOramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Daily Brief United States: Tesla , Adobe Systems, Nine Energy Service , Oramed Pharmaceuticals , Olin Corp, Earth Science Tech, Kardigan, Generac Holdings, General Motors, Nucor Corp and more - Smartkarma
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026 - GuruFocus
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oramed Pharmaceuticals Inc - TradingKey
Oramed Pharmaceuticals to join Russell 2000, 3000 indexes - Investing.com
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PR Newswire
June 2026 Penny Stocks To Watch For Potential Growth - Yahoo Finance
These healthcare stocks are combining strong gains with reasonable prices - MSN
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Oramed Pharmaceuticals (ORMP) Faces Selling Pressure; Key Levels in FocusTriple Bottom - newsline.com
Oramed Pharmaceuticals Q4 2025 Earnings: Positive EPS Surprise Driven by Non-Operating IncomeEarnings Beat Alert - newsline.com
Oramed Pharmaceuticals Inc. (ORMP) Q4 2025 Earnings: Surprise Profitability on Milestone RevenueEarnings Expansion Phase - newsline.com
ORMP Should I Buy - Intellectia AI
Oramed Pharmaceuticals (ORMP) Holds Near Key Support Amid Modest DeclineDemand Zone - The Legal Advocate
Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy - openPR.com
Oramed Pharmaceuticals (ORMP) Drops 8.9%: Support Level Under PressureNAAIM Exposure - The Legal Advocate
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Q4 2025 Results Meet Expectations — Revenue $N/AMargin Compression Risk - newsline.com
Oramed Pharmaceuticals Inc. Q1 2026 Financial Report: Key Investments, Marketable Securities, and Forward-Looking Statements - Minichart
Oramed: Q1 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary - TradingView
Oramed (NASDAQ: ORMP) swings to $38.3M Q1 profit on Alpha Tau and Scilex gains - Stock Titan
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifeward Ltd.16079622026 - SEC.gov
Oramed Pharmaceuticals (ORMP) Q4 2025 Financial OverviewIncome Pick - newser.com
Oramed Pharmaceuticals Delays Quarterly SEC Filing - TipRanks
Oramed Pharmaceuticals (NASDAQ: ORMP) notifies late Q1 2026 Form 10-Q filing - Stock Titan
About Us | Oil & Gas JournalOramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Stock Quote - FinancialContent
Oramed Pharmaceuticals (ORMP) Stock: Slides -0.74%, Support at $4.46 2026-05-15Buy Signals - newser.com
Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G - Stock Titan
Oramed Pharmaceuticals Discloses Investment at Lifeward with 49.9% Stake - TradingView
Oramed details Lifeward (LFWD) equity stake, notes and warrants - Stock Titan
Oramed (LFWD) reports 49.9% Lifeward stake, $9M notes and warrants - Stock Titan
Oramed Pharmaceuticals stock (US68403P1003): Oral drug delivery innovator for US diabetes market - AD HOC NEWS
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks - Yahoo Finance
Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30 - AD HOC NEWS
TradingKey - TradingKey
MSN Money - MSN
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oramed Pharmaceuticals Inc-Aktie (ORMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):